search
Back to results

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Primary Purpose

Meningioma

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Cabozantinib
Sponsored by
Baptist Health South Florida
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Meningioma focused on measuring Meningioma, central nervous system tumors, Recurrent meningioma, Progression meningioma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Histologic (preferred) or radiologic diagnosis of meningioma. All WHO grades (I, II and III) are allowed.
  2. All patients must have developed recurrent disease or progressive disease after receiving standard therapy (eg, radiation or surgery) >6 months ago or have been deemed ineligible to receive these therapies.
  3. Karnofsky Performance Status ≥50 (Appendix 1)
  4. Adequate Hematologic Function

(1) Absolute Neutrophil Count ≥ 1.5 x 10^9 / L without granulocyte colony-stimulating factor support.

(2) Platelet Count ≥ 100 x 10^9 / L without transfusion. (3) Hemoglobin ≥ 9 g/dL without transfusion within 7 days prior to screening assessment.

5. Adequate Renal Function ≥ 30 ml/min according to the Cockcroft-Gault formula (Appendix 5) 6. Adequate Hepatic Function including:

(1) Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (2) AST ≤ 3 x upper limit of normal (ULN) without liver metastasis (3) ALT ≤ 3 x upper limit of normal (ULN) without liver metastasis (4) AST or ALT ≤ 5 x upper limit of normal (ULN) for patients with liver metastasis (5) Patients with known Gilbert's syndrome may be included if total bilirubin ≤ x 3 ULN 7. Patients must have measurable disease by iRANO criteria (Section 13.2.2.1) 8. Women of childbearing potential must have negative serum pregnancy testing at screening. All women will be considered childbearing potential unless meeting criteria including:

(1) Achieved post-menopausal status as defined by cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause and have follicular stimulation hormone showing postmenopausal state. Women who have been amenorrhoeic for ≥12 months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anorexia, low body weight, ovarian suppression, anti-estrogen therapy or other medically inducible reasons.

(2) Documented hysterectomy or bilateral oophorectomy surgery (3) Medically confirmed ovarian failure (4) Sexually active participants and their partners must agree to use medically accepted methods of contraception during the study and for 4 months after discontinuing study treatment (Section 11.4).

9. Recovery of baseline CTCAE v5.0 Grade ≤1 toxicity related to prior study treatments unless adverse events are clinically non-significant per investigator's discretion and/or stable on supportive therapy if needed.

10. Patients must be willing and able to comply with trial protocol. This includes adhering to the treatment plan, scheduled visits, laboratory and other study procedures.

11. Serum albumin ≥ 2.8 g/dl 12. (PT)/INR or partial thromboplastin time (PTT) test < 1.3x the laboratory ULN

Exclusion Criteria:

  1. Prior treatment with cabozantinib
  2. Patients <18 years old
  3. Patients who are pregnant or breast-feeding.
  4. Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
  5. Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.

7. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.

8. Ejection Fraction (EF) ≤50% by echocardiogram (ECHO). Multi-gated acquisition scan (MUGA) should be obtained to estimate EF if quality of ECHO is insufficient.

9. Prior history of hypertensive encephalopathy at any time 10. History of congenital QT syndrome. 11. Corrected QT interval calculated by the Fridericia formula (QTcF) >500 ms within 14days of study registration (Appendix 6). If initial QTcF is >500 ms, two additional EKGs separated by at least 3 minutes should be performed, and if average of these consecutive results is QTcF is ≤ 500 ms, patient is eligible.

12. Unstable cardiac arrhythmia within 6 months prior to study registration date.

13. Urine Protein-to-Creatinine ratio (UPCR) >1 mg/mg or 24-hour urine protein > 1 gram (Appendix 5) 14. History of bleeding diathesis or significant unexplained coagulopathy (eg, in the absence of anticoagulation).

15. Clinical signs or symptoms of gastrointestinal obstruction requiring parenteral hydration, nutrition or feeding tube.

16. Uncontrolled effusion management (pleural effusion, pericardial effusion or ascites) requiring recurrent drainage procedures.

17. Active infection requiring parenteral antibiotic therapy. 18. History of either positive HCV RNA viral load or detectable anti-HCV antibody; HBV infection with HBV surface antigen detection and/or positive HBV DNA viral load.

19. Serious non-healing wound, ulcer, or bone fracture requiring intervention within 28 days prior to study registration date.

20. Known hypersensitivity to cabozantinib or any component in formulation. 21. Inability to swallow capsules, known intolerance to cabozantinib or its excipients, known malabsorption syndrome, or other conditions which impair intestinal absorption.

22. Other severe acute or chronic medical conditions, which may increase study risk per treating investigator's discretion.

23. Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:

a. Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).

b. Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.

24. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

  1. Cardiovascular disorders:
  2. Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.
  3. Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment.
  4. Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months before first dose of study treatment.
  5. Subjects with a diagnosis of incidental, sub-segmental PE or DVT within 6 months are allowed if stable, asymptomatic, and treated with a stable dose of permitted anticoagulation (see exclusion criterion #6) for at least 1 week before first dose of study treatment.
  6. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:
  7. The subject has evidence of any concurrent malignancy invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.
  8. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose of study treatment.

Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.

25. Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose of study treatment.

26. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease from another malignancy.

27. Other clinically significant disorders that would preclude safe study participation.

  1. Serious non-healing wound/ulcer/bone fracture.
  2. Uncompensated/symptomatic hypothyroidism.
  3. Moderate to severe hepatic impairment (Child-Pugh B or C). 28. Major surgery (e.g., laparoscopic nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 2 weeks before first dose of study treatment. Minor surgeries within 10 days before first dose of study treatment. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.

Sites / Locations

  • Miami Cancer Institute at Baptist Health, Inc.Recruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Cabozantinib

Arm Description

Participants will self-administer cabozantinib 60 mg at the same time daily by mouth on a continuous 28-day schedule. Participants will continue to take this medication as long as they are deriving benefit from it without significant treatment-related toxicities.

Outcomes

Primary Outcome Measures

Progression free survival (PFS)
Proportion of participants who from start of treatment to 6-months are free from objective tumor progression or death from any cause.

Secondary Outcome Measures

Objective response rate (ORR)
Proportion of participants with confirmed complete response (CR) or partial response (PR) assessed by Immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteria, relative to the total population of patients enrolled who initiate therapy.
Overall survival (OS)
Overall Survival (OS): duration of time from start of treatment until death from any cause. Patients lost-to follow up will be censored at last valid assessment.
Proportion of participants with adverse events
Proportion of participants who develop adverse events assessed by CTCAE v5.0 criteria.
Quality of life (QOL)
QOL will be measured by Functional Assessment of Cancer Therapy-Brain (FACT-Br) Version 4. The FACT-Br questionnaire is a 23-item survey, participants then rate each item on a Likert scale from 0 "not at all" to 4 "very much", and overall, higher ratings are suggestive of better quality of life. QOL will be assessed at the baseline, day 1 of every cycle (treatment days, every 4 weeks on 28-day cycle, and every 6 weeks on 42-day cycle).

Full Information

First Posted
June 15, 2022
Last Updated
October 5, 2023
Sponsor
Baptist Health South Florida
Collaborators
Exelixis
search

1. Study Identification

Unique Protocol Identification Number
NCT05425004
Brief Title
Cabozantinib for Patients With Recurrent or Progressive Meningioma
Official Title
A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 27, 2022 (Actual)
Primary Completion Date
November 2025 (Anticipated)
Study Completion Date
May 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Baptist Health South Florida
Collaborators
Exelixis

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Meningioma
Keywords
Meningioma, central nervous system tumors, Recurrent meningioma, Progression meningioma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cabozantinib
Arm Type
Experimental
Arm Description
Participants will self-administer cabozantinib 60 mg at the same time daily by mouth on a continuous 28-day schedule. Participants will continue to take this medication as long as they are deriving benefit from it without significant treatment-related toxicities.
Intervention Type
Drug
Intervention Name(s)
Cabozantinib
Other Intervention Name(s)
XL184, Cometriq, Cabometyx, BMS907351
Intervention Description
Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
Primary Outcome Measure Information:
Title
Progression free survival (PFS)
Description
Proportion of participants who from start of treatment to 6-months are free from objective tumor progression or death from any cause.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Objective response rate (ORR)
Description
Proportion of participants with confirmed complete response (CR) or partial response (PR) assessed by Immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteria, relative to the total population of patients enrolled who initiate therapy.
Time Frame
2 years
Title
Overall survival (OS)
Description
Overall Survival (OS): duration of time from start of treatment until death from any cause. Patients lost-to follow up will be censored at last valid assessment.
Time Frame
2 years
Title
Proportion of participants with adverse events
Description
Proportion of participants who develop adverse events assessed by CTCAE v5.0 criteria.
Time Frame
2 years
Title
Quality of life (QOL)
Description
QOL will be measured by Functional Assessment of Cancer Therapy-Brain (FACT-Br) Version 4. The FACT-Br questionnaire is a 23-item survey, participants then rate each item on a Likert scale from 0 "not at all" to 4 "very much", and overall, higher ratings are suggestive of better quality of life. QOL will be assessed at the baseline, day 1 of every cycle (treatment days, every 4 weeks on 28-day cycle, and every 6 weeks on 42-day cycle).
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Histologic (preferred) or radiologic diagnosis of meningioma. All World Health Organization (WHO) grades (I, II and III) are allowed. All patients must have developed recurrent disease or progressive disease after receiving standard therapy (e.g., radiation or surgery) > 6 months ago or have been deemed ineligible to receive these therapies. Karnofsky Performance Status ≥ 50. Adequate hematologic function: Absolute Neutrophil Count ≥ 1.5 x 10^9 / L without granulocyte colony-stimulating factor support. Platelet Count ≥ 100 x 10^9 / L without transfusion. Hemoglobin ≥ 9 g/dL without transfusion within 7 days prior to screening assessment. Adequate renal function: ≥ 30 ml/min according to the Cockcroft-Gault formula. Adequate hepatic function including: Total bilirubin ≤ 1.5 x upper limit of normal (ULN). Aspartate transaminase (AST) ≤ 3 x ULN without liver metastasis. Alanine transaminase (ALT) ≤ 3 x ULN without liver metastasis. AST or ALT ≤ 5 x ULN for patients with liver metastasis. Patients with known Gilbert's syndrome may be included if total bilirubin ≤ x 3 ULN. Patients must have measurable disease by iRANO criteria Women of childbearing potential must have negative serum pregnancy testing at screening. All women will be considered childbearing potential unless meeting criteria including: Achieved post-menopausal status as defined by cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause and have follicular stimulation hormone showing postmenopausal state. Women who have been amenorrhoeic for ≥12 months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anorexia, low body weight, ovarian suppression, anti-estrogen therapy or other medically inducible reasons. Documented hysterectomy or bilateral oophorectomy surgery. Medically confirmed ovarian failure. Sexually active participants and their partners must agree to use medically. accepted methods of contraception during the study and for 4 months after discontinuing study treatment Recovery of baseline CTCAE v5.0 Grade ≤1 toxicity related to prior study treatments unless adverse events are clinically non-significant per investigator's discretion and/or stable on supportive therapy if needed. Patients must be willing and able to comply with trial protocol. This includes adhering to the treatment plan, scheduled visits, laboratory and other study procedures. Serum albumin ≥ 2.8 g/dL. Prothrombin time (PT)/International Normalized Ratio (INR) or partial thromboplastin time (PTT) test < 1.3x the laboratory ULN. Exclusion Criteria Prior treatment with cabozantinib. Patients < 18 years old. Patients who are pregnant or breast-feeding. Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 3 years prior to the first dose of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast. Receipt of any type of cytotoxic, biologic, or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) with 2 weeks before first dose of study treatment. Ejection fraction (EF) ≤ 50% by echocardiogram (ECHO). Multi-gated acquisition scan (MUGA) should be obtained to estimate EF if quality of ECHO is insufficient. Prior history of hypertensive encephalopathy at any time. History of congenital QT syndrome. Correct QT interval calculated by the Fridericia formula (QTcF) > 500 ms within 14 days of study registration. If initial QTcF is >500 ms, two additional EKGs separated by at least 3 minutes should be performed, and if average of these consecutive results is QTcF is ≤ 500 ms, patient is eligible. Unstable cardiac arrhythmia within 6 months prior to study registration date. Urine Protein-to-Creatinine ratio (UPCR) >1 mg/mg or 24-hour urine protein > 1 gram. History of bleeding diathesis or significant unexplained coagulopathy (e.g., in the absence of anticoagulation). Clinical signs or symptoms of gastrointestinal obstruction requiring parenteral hydration, nutrition or feeding tube. Uncontrolled effusion management (pleural effusion, pericardial effusion or ascites) requiring recurrent drainage procedures. Active infection requiring parenteral antibiotic therapy. History of either positive hepatitis C virus (HCV) RNA viral load or detectable anti-HCV antibody; hepatitis B virus (HBV) infection with HBV surface antigen detection and/or positive HBV DNA viral load. Serious non-healing wound, ulcer, or bone fracture requiring intervention within 28 days prior to study registration date. Known hypersensitivity to cabozantinib or any component in formulation. Inability to swallow capsules, known intolerance to cabozantinib or its excipients, known malabsorption syndrome, or other conditions which impair intestinal absorption. Other severe acute or chronic medical conditions, which may increase study risk per treating investigator's discretion. Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following: Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH). Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions: Cardiovascular disorders: Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias. Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment. Stroke [including transient ischemic attack (TIA)], myocardial infarction (MI), or other ischemic event, or thromboembolic event [e.g., deep venous thrombosis (DVT), pulmonary embolism (PE)] within 6 months before first dose of study treatment. Subjects with a diagnosis of incidental, sub-segmental PE or DVT within 6 months are allowed if stable, asymptomatic, and treated with a stable dose of permitted anticoagulation (see exclusion criterion #6) for at least 1 week before first dose of study treatment. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation: The subject has evidence of any concurrent malignancy invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose of study treatment. Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment. Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose of study treatment. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease from another malignancy. Other clinically significant disorders that would preclude safe study participation. Serious non-healing wound/ulcer/bone fracture. Uncompensated/symptomatic hypothyroidism. Moderate to severe hepatic impairment (Child-Pugh B or C). Major surgery (e.g., laparoscopic nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 2 weeks before first dose of study treatment. Minor surgeries within 10 days before first dose of study treatment. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rupesh R Kotecha, M.D.
Phone
(786) 596-2000
Email
rupeshk@baptisthealth.net
First Name & Middle Initial & Last Name or Official Title & Degree
Paul Ferguson
Phone
(786) 527-8280
Email
paul.ferguson@baptisthealth.net
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rupesh R Kotecha, M.D.
Organizational Affiliation
Miami Cancer Institute at Baptist Health, Inc.
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yazmin Odia, M.D.
Organizational Affiliation
Miami Cancer Institute at Baptist Health, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Miami Cancer Institute at Baptist Health, Inc.
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rupesh R Kotecha, MD
Phone
786-596-2000
Email
RupeshK@baptisthealth.net
First Name & Middle Initial & Last Name & Degree
Paul Ferguson
Phone
(786) 527-8280
Email
paul.ferguson@baptisthealth.net
First Name & Middle Initial & Last Name & Degree
Rupesh R Kotecha, MD
First Name & Middle Initial & Last Name & Degree
Yazmin Odia, MD

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
31786276
Citation
Rogers CL, Won M, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Fogh SE, Youssef E, Deb N, Kwok Y, Robinson CG, Shu HK, Fisher BJ, Panet-Raymond V, McMillan WG, de Groot JF, Zhang P, Mehta MP. High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):790-799. doi: 10.1016/j.ijrobp.2019.11.028. Epub 2019 Nov 29.
Results Reference
background
PubMed Identifier
3945904
Citation
Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol. 1986 Mar;25(3):233-42. doi: 10.1016/0090-3019(86)90233-8.
Results Reference
background
PubMed Identifier
10223247
Citation
Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer. 1999 May 1;85(9):2046-56. doi: 10.1002/(sici)1097-0142(19990501)85:93.0.co;2-m.
Results Reference
background
PubMed Identifier
9414189
Citation
Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol. 1997 Dec;21(12):1455-65. doi: 10.1097/00000478-199712000-00008.
Results Reference
background
PubMed Identifier
29302064
Citation
Preusser M, Brastianos PK, Mawrin C. Advances in meningioma genetics: novel therapeutic opportunities. Nat Rev Neurol. 2018 Feb;14(2):106-115. doi: 10.1038/nrneurol.2017.168. Epub 2018 Jan 5.
Results Reference
background
PubMed Identifier
25812657
Citation
Yun S, Koh JM, Lee KS, Seo AN, Nam KH, Choe G. Expression of c-MET in Invasive Meningioma. J Pathol Transl Med. 2015 Jan;49(1):44-51. doi: 10.4132/jptm.2014.10.13. Epub 2015 Jan 15.
Results Reference
background
PubMed Identifier
25100872
Citation
Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan;17(1):116-21. doi: 10.1093/neuonc/nou148. Epub 2014 Aug 6.
Results Reference
background
PubMed Identifier
24268852
Citation
Chevreau C, Ravaud A, Escudier B, Amela E, Delva R, Rolland F, Tosi D, Oudard S, Blanc E, Ferlay C, Negrier S; French Group on Renal Cancer. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clin Genitourin Cancer. 2014 Feb;12(1):50-4. doi: 10.1016/j.clgc.2013.09.008. Epub 2013 Sep 28.
Results Reference
background
PubMed Identifier
18709663
Citation
Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008 Dec;47(12):1025-37. doi: 10.1002/gcc.20604.
Results Reference
background
PubMed Identifier
29016998
Citation
Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018 Jan 22;20(2):249-258. doi: 10.1093/neuonc/nox154.
Results Reference
background
PubMed Identifier
26406150
Citation
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Geczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.
Results Reference
background
PubMed Identifier
27279544
Citation
Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5.
Results Reference
background
PubMed Identifier
29309249
Citation
Escudier B, Powles T, Motzer RJ, Olencki T, Aren Frontera O, Oudard S, Rolland F, Tomczak P, Castellano D, Appleman LJ, Drabkin H, Vaena D, Milwee S, Youkstetter J, Lougheed JC, Bracarda S, Choueiri TK. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. J Clin Oncol. 2018 Mar 10;36(8):765-772. doi: 10.1200/JCO.2017.74.7352. Epub 2018 Jan 8.
Results Reference
background
PubMed Identifier
29550566
Citation
Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 May;94:115-125. doi: 10.1016/j.ejca.2018.02.012. Epub 2018 Mar 20. Erratum In: Eur J Cancer. 2018 Nov;103:287.
Results Reference
background
PubMed Identifier
29972759
Citation
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klumpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.
Results Reference
background
PubMed Identifier
26549824
Citation
Foxx-Lupo WT, Sing S, Alwan L, Tykodi SS. A Drug Interaction Between Cabozantinib and Warfarin in a Patient With Renal Cell Carcinoma. Clin Genitourin Cancer. 2016 Feb;14(1):e119-21. doi: 10.1016/j.clgc.2015.09.015. Epub 2015 Oct 3. No abstract available.
Results Reference
background
PubMed Identifier
25466707
Citation
Raizer JJ, Fitzner KA, Jacobs DI, Bennett CL, Liebling DB, Luu TH, Trifilio SM, Grimm SA, Fisher MJ, Haleem MS, Ray PS, McKoy JM, DeBoer R, Tulas KM, Deeb M, McKoy JM. Economics of Malignant Gliomas: A Critical Review. J Oncol Pract. 2015 Jan;11(1):e59-65. doi: 10.1200/JOP.2012.000560. Epub 2014 Dec 2.
Results Reference
background
PubMed Identifier
26509217
Citation
Grimm SA, Chamberlain MC. Bevacizumab and other novel therapies for recurrent oligodendroglial tumors. CNS Oncol. 2015;4(5):333-9. doi: 10.2217/cns.15.27. Epub 2015 Oct 28.
Results Reference
background
PubMed Identifier
27311730
Citation
Shih KC, Chowdhary S, Rosenblatt P, Weir AB 3rd, Shepard GC, Williams JT, Shastry M, Burris HA 3rd, Hainsworth JD. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol. 2016 Sep;129(2):281-8. doi: 10.1007/s11060-016-2172-3. Epub 2016 Jun 16.
Results Reference
background
Links:
URL
https://cancer.baptisthealth.net/
Description
Miami Cancer Institute

Learn more about this trial

Cabozantinib for Patients With Recurrent or Progressive Meningioma

We'll reach out to this number within 24 hrs